Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.

By J. Baselga, V. Semiglazov, Peter van Dam, A. Manikhas, M. Bellet, J. Mayordomo, Mario Campone, E. Kubista, R. Greil, G. Bianchi and 10 more. Journal of Clinical Oncology, 2009

639 citations recorded by the source corpus.

Subfields: Cancer Research, Genetics, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/71fc68e43a8cc761f5275bd45cadc91c4b030993

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

1. Carlos L. Arteaga

In Genetics

1. Carlos L. Arteaga
2. L. Gianni

In Molecular Biology

1. Carlos L. Arteaga
2. M. Sliwkowski
3. L. Gianni
4. M. Lacouture

Citations in the corpus

• Treatment of HER2-positive breast cancer: current status and future perspectives (2012, background): “ELATE (NCT01205217) II HER2+ operable stage I–IIIA BC (164) Lapatinib–epirubicin–cyclophosphamide paclitaxel– lapatinib vs epirubicin–cyclophosphamide paclitaxel– trastuzumab pCR in breast 2012”